JAN 0 3 2005

PTO/SB/08a/b (08-03) Approved for use through 07/31/2006. OMB 0551-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

. \	Taribid Westing	erwork Reduction Ac	of 1995, no persons are re	A.S. Patent and Tra equired to respond to a collection of	pproved for use through 07/31/2006. OMB 0651-0031 idemark Office; U.S. DEPARTMENT OF COMMERCE information unless it contains a valid OMB control number. Complete If Known
Sub	stitute for form 1449A/	в/РТО			Complete If Known
Ì				Application Number	09/499526
IN	<b>IFORMATI</b>	ON DISC	LOSURE	Filing Date	February 10, 2000
S	TATEMEN'	T BY AP	PLICANT	First Named Inventor	Kuanghui Lu
				Art Unit	1647
	(Use as man	y sheets as nec _	essary)	Examiner Name	R. M. Deberry
Sheet	1	of	4	Attorney Docket Number	CIBT-P01-058

					U.S. PATE	NT DOCUMENTS	
,	Examiner Initiats*		Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
			No.	Number-Kind Code <sup>2</sup> ( if known)		Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
K	7	$\cap$	AA	2002/0094346-A1	07-18-2002		
	L	ノ	AB	4,839,343	06-13-1989		
	Τ		AC	4,891,357	01-02-1990		
	Τ		AD	5,604,203	02-18-1997		
	Γ		AE	5,696,093	12-09-1997		
	Γ		AF	5,912,227	06-15-1999		
	Γ		AG	5,939,462	08-17-1999		
	Γ		AH	5,968,819	10-19-1999		
R	V	)	Al	6,013,622	01-11-2000		

ı	FOREIGN PATENT DOCUMENTS									
ı	Examiner Initials*		Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,			
			No.	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (# known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁰		
1	RO	abla	BA	EP-0 992 239-B1	03-12-2003			П		
1	M.	0	ВВ	WO-00/47219-A2	08-17-2000			П		
1	אוען		ВС	WO-00/68197-A1	11-16-2000					
1	1A 1	Ų	BD	WO-01/62737-A2	08-30-2001					
I	$\mathbb{Z}^{n}$	$\langle$	βE	WO-01/76631-A2	10-18-2001			П		
1	ZAM	Ø	∖BF	WO-2003/026591-A2	04-03-2003			П		
	<b>UNU</b>		BG	WO-99/15516-A1	04-01-1999					

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS							
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²					
Ru	GA	Adrian, T.E., et al., "Human Distribution and Release of a Putative New Gut Hormone, Peptide YY," Gastroenterology, 89:1070-7 (1985).						
8	СВ	Allen, J.M., et al., "Effects of Peptide YY and Neuropeptide Y on Gastric Emptying in Man," Digestion, 30:255-262 (1984).						
RY	CC	Asakawa, A., et al., "Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice," Peptides, 20:1445-1448 (1999).						
3	CD	Balasubramaniam, A., et al., "Structure-Activity Studies Including a $\psi$ (CH2-NH) Scan of Peptide YY (PYY) Active Site, PYY(22-36), for Interaction with Rat Intestinal PYY Receptors: Development of Analogues with Potent in Vivo Activity in the Intestine," J. Med. Chem., 43:3420-3427 (2000).						
\$N	ÇE	Batterham, R.L., et al., "Gut hormone PYY3-36 physiologically inhibits food intake," Nature, 418:650-654 (2002).						
PE	CF	Batterham, R.L., et al., "Inhibition of Food Intake in Obese Subjects by Peptide YY3-36," N Engl J Med, 349(10):941-948 (2003).						

Date Considered

PTC/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE to respond to a collection of information unless it contains a valid OMB control number.

Sub	stitute for form 1449A/I	в/РТО		Complete If Known			
				Application Number	09/499526		
- 11	<b>IFORMATION</b>	ON DIS	SCLOSURE	Filing Date	February 10, 2000		
S	TATEMEN'	T BY A	APPLICANT	First Named Inventor	Kuanghui Lu		
				Art Unit	1647		
	(Use as many	y sheets as	necessary)	Examiner Name	R. M. Deberry		
Sheet	2	of	4	Attorney Docket Number	CIBT-P01-058		

AND	CG	Bonaz, B., et al., "Peripheral peptide YY induces c-fos-like immunoreactivity in the rat brain," Neuroscience Letters, 163:77-80 (1993).
RIO	СН	Brown, K.K., et al., "A Novel N-Aryl Tyrosine Activator of Peroxisome Proliferator-Activated Receptor-y Reverses the Diabetic Phenotype of the Zucker Diabetic Fatty Rat," Diabetes,
		48:1415-1424 (1999).
400	Cl	Campfield, L.A., et al., "Recombinant Mouse OB Protein: Evidence for a Peripheral Signal Linking Adiposity and Central Neural Networks," Science, 269(5223):546-549 (1995).
ON	ÇJ	Chen, C.H. and Rogers, R.C., "Central inhibitory action of peptide YY on gastric motility in
MAI	)	rats;" Am. J. Physiol., 269:R787-R792 (1995).
MO	CK	Chen, C.H., et al., "Intracisternal injection of peptide YY inhibits gastric emptying in rats," Regulatory Peptides, 61:95-98 (1996).
h	CL	Clark, J.T., et al., "Neuropeptide Y (NPY)-induced feeding behavior in female rats: comparison
Algan		with human NPY ([Met17]NPY), NPY analog ([norLeu4]NPY) and peptide YY," Regulatory Peptides, 17:31-39 (1987).
YNN	СМ	Clark, J.T., et al., "Neuropeptide Y and Human Pancreatic Polypeptide Stimulate Feeding
W. V	Chi	Behavior in Rats," Endocrinology, 115(1):427-429 (1984).
<u> </u>	CN	Corp, E. S., et al., "Effect of fourth ventricular neuropeptide Y and peptide YY on ingestive and other behaviors", The American Physiological Society, 317-323 (1990)
11.0	co	Deng, X., et al., "PYY Potently Inhibits Pancreatic Exocrine Secretion Mediated Through CCK-
YW!	,	Secretin-Stimulated Pathways but Not 2-DG-Stimulated Pathways in Awake Rats," Digestive
	CP	Diseases and Sciences, 46(1):156-165 (2001).
4M)	OF .	Eberlein, G. A., et al, "A New Molecular Form of PYY: Structural Characterization of Human PYY (3-36) and PYY (1-36)", Peptides, 10: 797-803 (1989)
10 A	ca	Garlicki, J., et al., "Cholecystokinin receptors and vagal nerves in control of food intake in
PU		rats," Am. J. Physiol., 258:E40-E45 (1990).
000	CR	Gedulin, B.R., et al., "Assessment of Gastric Emptying from Appearance in Plasma of 3H from
$\mathcal{M}$	)	Gavaged [3-3H] Glucose in Conscious Rats: Effects of Amylin," Gastroenterological, Abstract,
	-	Vol. 108, No. 4 (April 1995).
HRU/)	CS	Gomez, G., et al., "Intestinal peptide YY: ontogeny of gene expression in rat bowel and trophic actions on rat and mouse bowel," Am. J. Physiol., 268:G71-G81 (1995).
	CT	Greeley, G.H., et al., "Inhibition of Gastric Acid Secretion by Peptide YY is Independent of
YIDW.)		Gastric Somatostatin Release in the Rat (42814)," Proceedings of the Society for Experimental
	<u> </u>	Biology and Medicine, 189:325-328 (1988).
410W 1	g)n	Grouzmann, E., et al, "Expression and Regulation of Neuropeptide Y in a Rat Insulinoma Cell
	¢v.	Line", Endocrinology, Abstract 519B (1993)
1/201	<b>y</b> v	Guan, et al., "Peptide-YY, a New Partner in the Negative Feedback Control of Pancreatic Secretion," Endocrinology, 128(2):911-916 (1991).
10	<del>CW</del>	Gue, M., et al., "Reversal by NPY, PYY and 3-36 molecular forms of NPY and PYY of
Md/	[	intracisternal CRF-induced inhibition of gastric acid secretion in rats," British Journal of
	/	Pharmacology, 118:237-242 (1996).
10/2	ex)	Hagan, M.M. and Moss, D.E., "Effect of Naloxone and Antidepressants on Hyperphagia
1	$\subseteq$	Produced by Peptide YY," Pharmacology Biochemistry and Behavior, 45:941-944 (1993).
The	CY	Halaas, J.L., et al., "Weight-Reducing Effects of the Plasma Protein Encoded by the Obese
1/4	CZ	Gene," Science, 269(5223):543-546 (1995).
	102	Haynes, J.M., et al., "Neuropeptide Y (NPY) and peptide YY (PYY) effects in the epididymis of the guinea-pig: evidence of a pre-junctional PYY-selective receptor," British Journal of
		Pharmacology, 122:1530-1536 (1997).
PAN	CA1	Hoentjen, F., et al., "Role of Circulating Peptide YY in the Inhibition of Gastric Acid Secretion
		by Dietary Fat in Humans," Scand J Gastroenterol, 35:166-171 (2000).
1/1/2 1/7	ÇB1	lyengar, S., et al., "Characterization of Neuropeptide Y-Induced Feeding In Mice: Do Y1-Y6
	<del></del>	Receptor Subtypes Mediate Feeding?," JPET, 289(2):1031-1040 (1999).
Examiner	V	KIVALO IM TWO DELLA Date 2/0/10
Signature		Considered 3/9/0
9619555_1		

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to the respond to a collection of information unless it contains a valid OMB control number.

on Act of 1996, no persons are Complete If Known Substitute for form 1449A/B/PTO Application Number 09/499526 **INFORMATION DISCLOSURE** February 10, 2000 Filing Date STATEMENT BY APPLICANT First Named Inventor Kuanghui Lu Art Unit 1647 (Use as many sheets as necessary) Examiner Name R. M. Deberry Attorney Docket Number CIBT-P01-058 Sheet of

PW	CC1	Kanatani, A., et al., "Role of the Y1 Receptor in the Regulation of Neuropeptide Y-Mediated Feeding: Comparison of Wild-Type, Y1 Receptor-Deficient, and Y5 Receptor-Deficient Mice," Endocrinology, 141(3):1011-1016 (2000).	i
1	CD1	Kato, K., et al., "CGRP Antagonists Enhance Gastric Acid Secretion in 2-h Pylorus-Ligated Rats," Peptides, 16(7):1257-1262 (1995).	
	CE1	Kawakubo, K., et al., "Intracisternal PYY inhibits gastric lesions induced by ethanol in rats: role of PYY-preferring receptors?," Brain Research, 854:30-34 (2000).	
T	CF1	Kimmel, J.R., et al., "Isolation and Characterization of Chicken Insulin," Endocrinology, 83:1323-1330 (1968).	
$\top$	CG1	Kopelman, P.G., "Obesity as a medical problem," Nature, 404:635-643 (2000).	_
T	CH1	Kushi, A., et al., "Obesity and mild hyperinsulinemia found in neuropeptide Y-Y1 receptor- deficient mice," Proc. Natl. Acad. Sci. USA, 95:15659-15664 (1998).	
	CI1	Lloyd, K.C.K., et al., "Inhibitory effect of PYY on vagally stimulated acid secretion is mediated predominantly by Y1 receptors," Am. J. Physiol., 270:G123-G127 (1996).	
	CJ1	Malaisse-Lagae, F., et al., "Pancreatic polypeptide: A possible role in the regulation of food intake in the mouse," Experientia 33, 915-917 (1977).	
	CK1	Marsh, D.J., et al., "Role of the Y5 neuropeptide Y receptor in feeding and obesity," Nature Medicine, 4(6):718-721 (1998).	
	CL1	Michel, M.C., et al., "XVI. International Union of Pharmacology Recommendations for the Nomenclature of Neuropeptide Y, Peptide YY, and Pancreatic Polypeptide Receptors," Pharmacological Reviews, 50(1):143-150 (1998).	
	CM1	Morley, J.E., et al., "Modulation of food intake by peripherally administered amylin," Am. J. Physiol., 267:R178-R184 (1994).	
	CN1	Morley, J.E., et al., "Peptide YY (PYY), a potent orexigenic agent," Brain Research, 341:200-203 (1985).	
	CO1	Munson, P.J. and Rodbard, D., "LIGAND: A Versatile Computerized Approach for Characterization of Ligan-Binding Systems," Analytical Biochemistry, 107:220-239 (1980).	
	CP1	Nakajima, M., et al., "Effects of Pancreatic Polypeptide Family Peptides on Feeding and Learning Behavior in Mice," The Journal of Pharmacology and Experimental Therapeutics, 268(2):1010-1014 (1994).	
T	CQ1	Naslund, E., et al., "Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men," International Journal of Obesity, 23:304-311 (1999).	
	CR1	Okada, S., et al, "Peripherally Not Centrally Administered Peptide YY (PYY) Decreases High Fat Diet Intake", Endocrinology, Abstract 5208 (1993)	
	CS1	Pappas, T.N., et al., "Peptide YY Release by Fatty Acids is Sufficient to Inhibit Gastric Emptying in Dogs," Gastroenterology, 91:1386-9 (1986).	
	CT1	Pelleymounter, M.A., et al., "Effects of the Obese Gene Product on Body Weight Regulation in Ob-Ob Mice," Science, 269(5223):540-543 (1995).	
	CU1	Rissanen, A., et al., "Risk of disability and mortality due to overweight in a Finnish population," Br Med J, 301:835-837 (1990).	
	CV1	Savage, A.P., et al., "Effects of peptide YY (PYY) on mouth to caecum intestinal transit time and on the rate of gastric emptying in healthy volunteers," Gut, 28:166-170 (1987).	
$\int$	CW1	Scatchard, G., "The Attractions of Proteins For Small Molecules and lons", Annals New York Academy of Sciences, pp. 660-672.	
$\int$	CX1	Schwartz, M.W., et al., "Central nervous system control of food intake," Nature, 404:661-671 (2000).	_
I	CY1	Stanley, B.G., et al., "Paraventribular Nucleus Injections of Peptide YY and Neuropeptide Y Preferentially Enhance Carbohydrate Ingestion," Peptides, 6:1205-1211 (1985).	_
$\int_{-\infty}^{\infty}$	CZ1	Surwit, R.S., et al., "Differential Effects of Fat and Sucrose on the Development of Obesity and Diabetes in C57BL/6J and A/J Mice," Metabolism, 44(5):645-651 (1995).	_
	CA2	Maniguchi, H., et al., "Pharmacological profile of T-0632, a novel potent and selective CCK(a)	_
$\mathbf{L}_{I}$			

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Sut	ostitute for form 1449A/B/P	το		Complete if Known		
				Application Number	09/499526	
11	<b>NFORMATIOI</b>	N DI	SCLOSURE	Filing Oate	February 10, 2000	
S	TATEMENT	BY A	APPLICANT	First Named Inventor	Kuanghui Lu	
				Art Unit	1647	
	(Use as many sh	ieets as	s necessary)	Examiner Name	R. M. Deberry	
Sheet	4	of	4	Attorney Docket Number	CIBT-P01-058	

		receptor antagonist, in vivo," European Journal of Pharmacology, 312:227-233 (1996).	
Om	CB2	Tatemoto, K., "Neuropeptide Y: Complete Amino Acid Sequence of the Brain Peptide," Proc. Natl. Acad. Sci. USA, 79:5485-5489 (1982).	
MA	CC2	Tatemoto, K., et al., "Neuropeptide Y-a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide," Nature, 296:659-660 (1982).	
MY	CD2	Ueno, N., et al., "Decreased Food Intake and Body Weight in Pancreatic Polypeptide- Overexpressing Mice," Gastroenterology, 117:1427-1432 (1999).	
Maxi	ÆE2	Verchere, C. B., et al, "Major Species Variation in the Expression of Galanin mRNA in Mammalian Celiac Ganglion", Endocrinology, Abstract 517B (1993)	
RO	€F2	Wang, Z. L., et al, "Co-Release of Neuropeptide Y With Insulin Following Dexamethasone", Endocrinology, Abstract 518B (1993)	
MO	CG2	Widdowson, P.S., et al., "Distribution of [Leu31,Pro34]NPY-sensitive, BIBP3226-insensitive [1251]PYY(3-36) binding sites in rat brain: possible relationship to Y5 NPY receptors," Brain Research, 778:242-250 (1997).	
PU	CH2	Wiley, J.W., et al., "Mechanism of Action of Peptide YY to Inhibit Gastric Motility," Gastroenterology, 100:865-872 (1991).	
Re	CI2	Yang, H. and Tache, Y., "PYY in brain stem nuclei induces vagal stimulation of gastric acid secretion in rats," Am. J. Physiol., 268:G943-G948 (1995).	
40	CJ2 )	Yang, H., et al., "PYY-preferring receptor in the dorsal vagal complex and its involvement in PYY stimulation of gastric acid secretion in rats," British Journal of Pharmacology, 123:1549-1554 (1998).	
-KW	CK2	Yoshinaga, K., et al., "Structural requirements of peptide YY for biological activity at enteric sites," Am. J. Physiol., 263:G695-G701 (1992).	
Jan		Young, AA, et al., "Genetically Obese (OB/OB) Mice Are More Sensitive To Amylin and Endotoxin Induced Suppression of Food Intake", Amylin Pharmaceuticals Inc., Program & Abstracts, Vol. 1: June 12 & 13 (1996).	
KO		Zai, H., et al., "Effect of peptide YY on gastric motor and secretory activity in vagally innervated and denervated corpus pouch dogs," Regulatory Peptides, 61:181-188 (1996).	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Man a cont		1
Examiner Signature	Date Considered	3/9/05
9619555_1		7,17

<sup>&#</sup>x27;Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.